Celcuity Inc. is under investigation by Pomerantz LLP for possible securities fraud following a delayed commercial launch announcement of its breast cancer drug Revtorpyk. The FDA approved the drug, but the launch was pushed to late Q3 2026, later than analysts expected, causing the stock to fall 17.6% on July 15, 2026. This delay and the subsequent stock drop have raised concerns about the company's disclosures and business practices. Investors are advised to contact Pomerantz LLP if they believe they were affected.
Three specialty semiconductor companies—Navitas Semiconductor, Alpha and Omega Semiconductor, and Tower Semiconductor—are positioned to benefit from AI infrastructure growth beyond the well-known megacaps. Navitas leads in 800V DC architecture for AI...
In August 2026, the three major US cloud providers—Microsoft Azure, Amazon AWS, and Google Cloud—reported strong revenue growth driven by heavy AI infrastructure investments. Azure grew 43% in Q4 FY2026, AWS posted 36.7% growth, and Google Cloud surg...
Five US-listed companies—Verizon, Altria, Enterprise Products Partners, Realty Income, and Amgen—are highlighted as safe high-yield dividend stocks for August 2026. Each has a long history of uninterrupted dividend payments and recently raised or rea...
XRP price remains around $1 after a 3.2% drop over the past week, with whale transfers to Binance falling to $61 million on a three-month average, the lowest since 2021. Reduced whale inflows suggest less immediate selling pressure, a positive sign, ...
CACI International, a leading government and IT contractor with a $14 billion market cap, is rated a hold due to lagging profitability despite strong growth metrics. The company is pivoting towards technology-driven contracts, especially in defense, ...
